AZN Jul 2024 77.000 call
| Previous Close | 2.5100 |
| Open | 2.5100 |
| Bid | 1.4500 |
| Ask | 1.7500 |
| Strike | 77.00 |
| Expire Date | 2024-07-05 |
| Day's Range | 2.5100 - 2.5100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 93 |
ZacksAstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
- Yahoo Finance Video
Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names have been often cited as top picks in the pharmaceutical industry, are there hidden gems to look out for or do Eli Lilly and Novo Nordisk remain at the top of the class? Mizuho Healthcare Equity Strategist Jared Holz joins Morning Brief to give insight into the healthcare sector and what investors should keep in mind moving forward. "I think for me, Novo and Lilly are still going to be the top two. You know, as long as they are dominating in this kind of section of the market, it's really tough to not ride these a little bit longer, as far as other players in the GLP one market that might emerge that are of interest or intrigue to investors," Holz says. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China
ReutersChina approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
AstraZeneca said the approval by China's National Medical Products Administration (NMPA) was based on trials which showed that patients given the combination treatment lived without the disease getting worse longer than those given just Tagrisso. The median progression-free survival of patients treated with Tagrisso and chemotherapy was 25.5 months, 8.8 months more than those treated with just Tagrisso.
